TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Induction of NRF2 target gene transcripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurological examination to evaluate long-term safety in patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of cervical neoplasia in HIV positive women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of cervical neoplasia in HIV negative women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Healthcare utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in migraine headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hernia detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of no reflow phenomenon
Endpoint domain: Adverse events/effects
Primary endpoint: Time taken to recruit planned sample
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adverse events associated with the intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients completed the exercise log
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence and intensity of post-obturation pain
Endpoint domain: Adverse events/effects
Primary endpoint: ECG interval changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Holter implementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial Inflammation Response to a High-fat Meal Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Child developmental milestones
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Left Ventricle Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Function Index (E/A Ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Pressure at Maximum Exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents (KINDL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Biomarker u-NAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biomarkers Nephrocheck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal oxygen delivery and blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With ≥30% Improvement in JIA ACR Core Set
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Decreases in Oral Corticosteroid Dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in cardiopulmonary variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in RASS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in St. George's Respiratory Questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Who Filled at Least 90 Days Supply of Fesoterodine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in sleep continuity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Surgery Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in mean Gli-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study Recruitment Success
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total steps of incorrect operations
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in conversion of IGT to diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Depression diagnosis and depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in endometrial histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum pH After 14 Days of Use of Dentifrice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Diabetes Self-care Activities at Three Weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline Diabetes Knowledge at Three Weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastric pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: freedom from any VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Subjects Experiencing a Major Adverse Event (MAE) Within 30 Days Post-implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Both Technical Success at the Time of Index Procedure and Treatment Success at 12-months Post-implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood glucose level during 120 minutes after meal start
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Count of mild hypoglycemic events (blood glucose<75)
Endpoint domain: Adverse events/effects
Primary endpoint: Count of hyperglycemia events (blood glucose>300)
Endpoint domain: Adverse events/effects
Primary endpoint: Effects of aerobic training compared to conventional motor training on global clinical disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects of aerobic training compared to conventional motor training on walking ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects of aerobic training compared to conventional motor training on spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women with GBS infection
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic Allograft Damage Index (CADI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive assessment scale score (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adequate Bowel Preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Western Ontario and McMaster Universities Arthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients showing good compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of breast cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adherence to diet intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of lymphocele and lymphatic ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Median Puregon® Dose (IU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients who are stable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects of therapeutic intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social activity
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Biometric data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anatomical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MVPA Maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Dabigatran AUC0-∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Dabigatran Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjects' weight (% total body loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUCt) of Bazedoxifene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUCt) of Cholecalciferol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of Bazedoxifene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of Cholecalciferol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurofilament light chain levels in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of symptomatic confirmed DVT, PE, or fatal PE
Endpoint domain: Mortality/survival
Primary endpoint: Continuous Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean time to reduce active lesions by 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Cerebral edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Impact on participants mental status concerning PTSD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact on participants mental status regarding depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact on participants ability to deal with health related problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in Procedural Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence rates of CAP
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Reversible Defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of Tat protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Eating Disorders Inventory-3 (EDI-3) drive for thinness (EDI-DT) scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Eating Disorders Inventory-3 (EDI-3) body dissatisfaction (EDI-BD) scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: step characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gait Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of total testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: rate of patients using hospital care in emergency
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of patients shedding virus from the oropharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in marginal bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Bowel Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change of pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hunger, satiety and desire to eat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Percent of CD44+/ CD24+/ ESA+ Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of serum antibody neutralization of autologous (HIV-1 BG505) and other heterologous Tier 2 HIV-1 strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnitude of serum antibody neutralization of autologous (HIV-1 BG505) and other heterologous Tier 2 HIV-1 strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of liver and spleen stiffness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days to Complete Alignment of Mandibular Anterior Teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative glucagon counterregulation (GCR) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of participants achieving endoscopic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse Events (AEs), Serious Adverse Events (SAEs) based on severity and withdrawals due to adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Acute brain injury severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from MACCE
Endpoint domain: Mortality/survival
Primary endpoint: Clinical tissue healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-segment late-loss at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of Influenza virus or Enterovirus 71
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Standardized Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Whole blood gene expression changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of true graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of grades II-IV acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Lactulose breath test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Health Questionnaire results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Adherence Measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Baseline Pre-bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: End-value Pre-bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean dose of steroid to maintain minimal manifestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-Weighted Average Change in Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Progression of Delayed Cortical Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 24h blood pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infection-free period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Actigraphic Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who have recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual assessment of lung lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Semiquantitative assessment of lung lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Treatment-emergent Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in reported consumption frequency of fruit and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of Events Score (IES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with high suPAR level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of PCV-1 DNA in stool samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of serum anti-PCV-1 antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percent of Breast Epithelial Cells With Ki-67 Immunocytochemical Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of diagnostic model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in mean diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline to the End of the Maintenance Period in International Restless Legs Rating Scale (IRLS) Sum Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Clinical Global Impressions (CGI) Item 1 to the End of the Maintenance Period
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Acute FMF Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of ex vivo expanded T-cells
Endpoint domain: Adverse events/effects
Primary endpoint: Non-invasive hemodynamic parameter measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mini Balance Evaluations Systems Test (MiniBEST Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: voiding quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Peak Troponin I value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin-stimulated Glucose Disposal Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal oxygen desaturation index (ODI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SCORAD (Severity Scoring of Atopic Dermatitis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Development of Acute Kidney Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Resolution or major reduction in PDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of aflibercept injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of vessels detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with lesion area covered by granulation tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discussion about prognosis of MDS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in cough severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in cough related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma Glucose (PG) Response to Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Hypoglycemia Immediately Following Exercise
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Nocturnal Hypoglycemia Following Exercise
Endpoint domain: Adverse events/effects
Primary endpoint: uptake of 68Ga-PSMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AAA volume growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial function evaluated by Reactive Hyperemia Index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Side effects preventing surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Variance in edema index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of PDT with temoporfin
Endpoint domain: Adverse events/effects
Primary endpoint: mean actual sleep time
Endpoint domain: Life impact
Endpoint subdomain: Sleep